Your browser doesn't support javascript.
loading
Decreased memory B cell frequencies in COVID-19 delta variant vaccine breakthrough infection.
Tay, Matthew Zirui; Rouers, Angeline; Fong, Siew-Wai; Goh, Yun Shan; Chan, Yi-Hao; Chang, Zi Wei; Xu, Weili; Tan, Chee Wah; Chia, Wan Ni; Torres-Ruesta, Anthony; Amrun, Siti Naqiah; Huang, Yuling; Hor, Pei Xiang; Loh, Chiew Yee; Yeo, Nicholas Kim-Wah; Wang, Bei; Ngoh, Eve Zi Xian; Salleh, Siti Nazihah Mohd; Chavatte, Jean-Marc; Lim, Alicia Jieling; Maurer-Stroh, Sebastian; Wang, Lin-Fa; Lin, Raymond Valentine Tzer Pin; Wang, Cheng-I; Tan, Seow-Yen; Young, Barnaby Edward; Leo, Yee-Sin; Lye, David C; Renia, Laurent; Ng, Lisa Fp.
Afiliação
  • Tay MZ; A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore.
  • Rouers A; A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore.
  • Fong SW; A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore.
  • Goh YS; A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore.
  • Chan YH; A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore.
  • Chang ZW; A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore.
  • Xu W; Singapore Immunology Network, A*STAR, Singapore City, Singapore.
  • Tan CW; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore City, Singapore.
  • Chia WN; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore City, Singapore.
  • Torres-Ruesta A; A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore.
  • Amrun SN; A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore.
  • Huang Y; A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore.
  • Hor PX; A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore.
  • Loh CY; A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore.
  • Yeo NK; A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore.
  • Wang B; Singapore Immunology Network, A*STAR, Singapore City, Singapore.
  • Ngoh EZX; Singapore Immunology Network, A*STAR, Singapore City, Singapore.
  • Salleh SNM; Singapore Immunology Network, A*STAR, Singapore City, Singapore.
  • Chavatte JM; National Centre for Infectious Diseases, Singapore City, Singapore.
  • Lim AJ; National Public Health Laboratory, National Centre for Infectious Diseases, Singapore City, Singapore.
  • Maurer-Stroh S; National Centre for Infectious Diseases, Singapore City, Singapore.
  • Wang LF; National Public Health Laboratory, National Centre for Infectious Diseases, Singapore City, Singapore.
  • Lin RVTP; Bioinformatics Institute, A*STAR, Singapore City, Singapore.
  • Wang CI; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore City, Singapore.
  • Tan SY; SingHealth Duke-NUS Global Health Institute, Singapore City, Singapore.
  • Young BE; National Centre for Infectious Diseases, Singapore City, Singapore.
  • Leo YS; National Public Health Laboratory, National Centre for Infectious Diseases, Singapore City, Singapore.
  • Lye DC; Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, Singapore.
  • Renia L; Singapore Immunology Network, A*STAR, Singapore City, Singapore.
  • Ng LF; Department of Infectious Diseases, Changi General Hospital, Singapore City, Singapore.
EMBO Mol Med ; 14(3): e15227, 2022 03 07.
Article em En | MEDLINE | ID: mdl-34994081
The SARS-CoV-2 Delta (B.1.617.2) variant is capable of infecting vaccinated persons. An open question remains as to whether deficiencies in specific vaccine-elicited immune responses result in susceptibility to vaccine breakthrough infection. We investigated 55 vaccine breakthrough infection cases (mostly Delta) in Singapore, comparing them against 86 vaccinated close contacts who did not contract infection. Vaccine breakthrough cases showed lower memory B cell frequencies against SARS-CoV-2 receptor-binding domain (RBD). Compared to plasma antibodies, antibodies secreted by memory B cells retained a higher fraction of neutralizing properties against the Delta variant. Inflammatory cytokines including IL-1ß and TNF were lower in vaccine breakthrough infections than primary infection of similar disease severity, underscoring the usefulness of vaccination in preventing inflammation. This report highlights the importance of memory B cells against vaccine breakthrough and suggests that lower memory B cell levels may be a correlate of risk for Delta vaccine breakthrough infection.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Idioma: En Ano de publicação: 2022 Tipo de documento: Article